18th CANADIAN MELANOMA CONFERENCE 2024: Merck Breakfast Symposium: Preparing for the Patient Discussion with OurStage II B/C Adjuvant Melanoma Patient – Dr. Elaine McWhirter & Kathy Barnard
OR
Learning Objectives
- Describe key clinical trial data from 2023 in the management of melanoma and understand the impact on Canadian practices.
- Understand the latest strategies in melanoma as they pertain to medical oncology, pathology, radiation, and surgery.
- Implement approaches that maximize patient standard of care in melanoma
Co-Chairs
Dr. Vanessa Bernstein
Dr. Teresa Petrella
Speakers
Dr. Elaine McWhirter
Kathy Barnard
This program has been made possible through unrestricted support from Merck
Studies/trials discussed:
- Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
- Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
